Medical Devices - Cardiac Surgery & Neuromodulation
Strategic Profile
LivaNova is pursuing strategic growth in high-growth segments such as obstructive sleep apnea and digital health for neuromodulation, while maintaining durable market share and profit gains in core Cardiopulmonary and Epilepsy businesses. The company is investing in advanced R&D, digital capabilities with FDA-approved platforms, and scaling next-generation manufacturing while deleveraging its balance sheet.
Cyborg Score Rationale
Full-year 2025 adjusted diluted earnings per share of $3.90 with Q4 strong performance suggests operational execution. The company completed early repayment of $200M in term facilities and $58M in convertible notes, with full repayment of remaining debt in January 2026. However, valuation compression is likely as growth moderates and R&D costs rise.
Top Insights
CMS increased reimbursement for VNS Therapy for Drug-Resistant Epilepsy effective January 1, 2026, significantly reducing a known barrier to procedure penetration.
FDA approved LivaNova's cloud-based digital health platform for epilepsy, establishing the foundation for a Connected Care roadmap with initial clinician portal rollout.
2026 includes manufacturing scale-up of next-generation oxygenator, OSA clinical trial device PMA approval, and CMS reimbursement reconsideration submission for difficult-to-treat depression.
Significant debt reduction with full repayment of remaining term facilities in January 2026, improving financial flexibility.
Named Competitors
Cardiopulmonary Bypass Devices — Diversified medical device leader with cardiac surgery portfolio